Are Generic Cancer Medicines Safe? Guide for Filipino Families

Generic vs branded: what is actually the same

When the patent on an original cancer medicine runs out, other companies may make their own versions. The US Food and Drug Administration explains that an approved generic has the same active ingredient as the brand-name medicine, in the same strength, the same form (such as a tablet or an injection) and given the same way. It is expected to work the same way and to carry the same benefits and risks.

Philippine law is built around this idea. Under the Generics Act of 1988 (Republic Act 6675), a medicine's generic name is the name of its active ingredient. Doctors must write prescriptions using the generic name, and may add a brand name if they wish. On branded products, the generic name must appear prominently, right above the brand name. Drug outlets must also tell you about other products with the same generic name and their prices, so you can compare.

What usually differs is the brand name, the company, the packaging and the price. The active ingredient, the part that treats the illness, is the same.

• Same active ingredient (the generic name on your prescription)
• Same strength, for example the same milligrams per tablet or vial
• Same dosage form, such as tablet, capsule or injection
• Same route, such as by mouth or into a vein

Bioequivalence: how regulators check that a generic works the same

Having the same ingredient on paper is not enough. Regulators also ask whether the body takes in the medicine the same way. "Bioavailability" means how fast and how much of the active ingredient is absorbed. Two products are "bioequivalent" when there is no significant difference between them in this. The US FDA requires approved generics to be bioequivalent to the brand and to be made under the same strict manufacturing standards, and it inspects factories.

In the Philippines, bioavailability and bioequivalence (BA/BE) testing for certain medicines was required by the Department of Health in Administrative Order 67 of 1989 and enforced through two circulars of the Bureau of Food and Drugs (now FDA Philippines) in 1997. In 2014 the Supreme Court declared those circulars valid and stressed that the State, through the FDA, must make sure generic medicines on the market are safe and effective. Which medicines need a full BE study is set by FDA Philippines rules that change over time, so ask your pharmacist or FDA Philippines if you want to know what applied to a specific product.

Biosimilars: the lower-cost versions of biologic cancer medicines

Many modern cancer medicines are biologics, made from living cells rather than simple chemicals. Because they are so complex, they cannot be copied exactly. Their lower-cost versions are called biosimilars. The US FDA describes a biosimilar as highly similar to the original (the "reference product") with no clinically meaningful differences from it. The American Cancer Society lists biosimilars for cancer biologics such as trastuzumab, rituximab and bevacizumab, and for supportive medicines such as filgrastim and pegfilgrastim, which help protect against infection during chemotherapy.

The American Cancer Society notes that biosimilars go through more testing than ordinary generics, including clinical trials against the original. A 2022 review in JAMA Oncology looked at 31 studies of biosimilars for three original cancer medicines, involving 12,310 patients, and found the biosimilars statistically indistinguishable from the originals on the efficacy measures used.

In the Philippines, Administrative Order 2014-0016 requires companies dealing in biosimilars to follow the World Health Organization's guidelines for evaluating them, and an FDA Philippines advisory (No. 2023-0771) directed them to follow the WHO's updated 2022 guidelines. Whether to use a biosimilar, or switch to one mid-treatment, is a decision for your oncologist.

Why prices differ, and what a low price does not mean

According to the US FDA, generic makers do not have to repeat the animal and human studies the original company ran, which lowers their costs, and several generics are often approved for the same medicine, so competition tends to push prices down. Biosimilar makers can likewise rely on the regulator's earlier finding that the original biologic is safe and effective. The US FDA states that the lower cost of biosimilars is not a reflection of their effectiveness or safety.

Prices can also vary from seller to seller. A fair difference is normal, but a price far below everyone else's from an unknown seller, especially online, is a reason to check the product and seller first. For current prices on our own range, see our price list.

How to check a product and seller on verification.fda.gov.ph

FDA Philippines runs a free verification portal at verification.fda.gov.ph. Since its upgrade in early 2026, news reports citing the Department of Health say you can search by keyword, product name, registration number or company name, by typing or by voice. Results show the product's registration record, including its classification, manufacturer, trader and the registration's issue and expiry dates, plus any FDA advisories about it. The Health Secretary has warned that unregistered products are illegal and that buying them puts you at risk.

This matters because the World Health Organization estimates that at least 1 in 10 medicines in low- and middle-income countries is substandard or falsified. Such products can contain the wrong ingredient or the wrong amount, which can lead to treatment failure, and some contain harmful substances.

• Search the exact product name or registration number and check that the generic name, strength, form and manufacturer match the box in your hand.
• Check that the registration is still valid and read any FDA advisory shown for that product.
• Search the pharmacy, distributor or online seller by company name to see whether it is listed as a licensed establishment.
• Look at the pack itself: Philippine law requires the generic name above any brand name, the manufacturer's name and country, and the manufacturing and expiry dates.
• If the product or seller does not appear, or the details do not match, do not use it. Ask your pharmacist or oncology nurse, and report it to FDA Philippines. The one exception is a medicine not yet registered here that is covered by a Compassionate Special Permit (CSP) your doctor obtained from FDA Philippines. Such a product will not show as registered, so ask the seller for a copy of the CSP.

Questions to ask your doctor and pharmacist

Cancer treatment is planned carefully, so do not change products on your own, even to a registered generic or biosimilar. Bring these questions to your next consultation.

• Is this generic or biosimilar registered with FDA Philippines?
• Is it all right to use a generic or biosimilar for my treatment, or to switch from the brand?
• If I switch, should I tell the chemotherapy unit which product I used in each cycle?
• How should this medicine be stored and transported? Some must be kept cold.
• Is there a guarantee letter or other assistance I can use for this medicine?

Where 2MG Inc. fits in

2MG Inc. is an FDA Philippines-licensed drug importer, distributor and wholesaler (License to Operate CDRR-NCR-DI/E/W-31324, issued 1 April 2024) specialising in oncology and hematology medicines. Our products come from facilities recognised by the WHO, PIC/S, US FDA, EU GMP or UK MHRA, a pharmacist checks every prescription, and medicines that must stay cold are shipped in cold-chain packaging. You can check our licence number with FDA Philippines, and see current prices on our price list.